As prostate cancers progress to hormone refractory metastatic disease, usually under conditions of androgen deprivation or complete androgen blockade, the epithelial AR is widely believed to have acquired the capacity to drive tumour growth. This evidence concerns the gene AR and prostate carcinoma.